Payment overview · 2025
General Payments
$528.78
28 reported records · 13 companies
Healthcare provider profile · identity verified
John Nicholson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STATESVILLE, NC · NPI 1497723795
Verified facts
What the public records show
CMS Open Payments records show John Nicholson, MD received $528.78 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.92 | 15.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.44 | 15.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.24 | 12.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.99 | 8.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.29 | 7.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.83 | 7.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.34 | 6.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.44 | 6.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.60 | 4.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.44 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.62 | 3.9% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.78 | 3.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.85 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $528.78 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.92 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.80 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.68 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 505 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 123 |
| Gabapentin | Gabapentin | 390 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 81 |
| Losartan Potassium | Losartan Potassium | 250 | 72 |
| Omeprazole | Omeprazole | 236 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 233 | 41 |
| Prednisone | Prednisone | 218 | 145 |
| Metformin Hcl Er | Metformin Hcl | 209 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 62 |
| Lisinopril | Lisinopril | 195 | 61 |
| Carvedilol | Carvedilol | 169 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 163 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 59 |
| Alprazolam | Alprazolam | 149 | 25 |
| Simvastatin | Simvastatin | 146 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 25 |
| Eliquis | Apixaban | 142 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 41 |
| Furosemide | Furosemide | 135 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 135 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 35 |
| Allopurinol | Allopurinol | 130 | 38 |
| Famotidine | Famotidine | 128 | 44 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 127 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 36 |
| Metformin Hcl | Metformin Hcl | 124 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 42 |
| Meloxicam | Meloxicam | 112 | 39 |
| Ezetimibe | Ezetimibe | 110 | 34 |
| Valsartan | Valsartan | 108 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 105 | 33 |
| Jardiance | Empagliflozin | 98 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 21 |
| Montelukast Sodium | Montelukast Sodium | 92 | 26 |
| Glimepiride | Glimepiride | 89 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 30 |
| Ozempic | Semaglutide | 89 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 89 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 23 |
| Potassium Chloride | Potassium Chloride | 86 | 22 |
| Diazepam | Diazepam | 84 | 30 |
| Sertraline Hcl | Sertraline Hcl | 83 | 22 |
| Clonazepam | Clonazepam | 80 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 23 |
| Mounjaro | Tirzepatide | 78 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 19 |
| Doxepin Hcl | Doxepin Hcl | 76 | 17 |
| Azithromycin | Azithromycin | 74 | 63 |
| Spironolactone | Spironolactone | 74 | 27 |
| Tramadol Hcl | Tramadol Hcl | 72 | 21 |
| Finasteride | Finasteride | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 28 |
| Xarelto | Rivaroxaban | 66 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Buspirone Hcl | Buspirone Hcl | 60 | 16 |
| Fluconazole | Fluconazole | 59 | 38 |
| Trazodone Hcl | Trazodone Hcl | 58 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | 12 |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 16 |
| Synthroid | Levothyroxine Sodium | 48 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 19 |
| Aripiprazole | Aripiprazole | 40 | 12 |
| Atenolol | Atenolol | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 27 |
| Nystatin | Nystatin | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 22 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Nexium | Esomeprazole Magnesium | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $528.78 · 28 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BEXSERO, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, OPSUMIT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UPTRAVI, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error